These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18342810)

  • 1. New approaches in acute myeloid leukemia.
    Blum W; Marcucci G
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):29-41. PubMed ID: 18342810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia.
    Hamadani M; Awan FT
    Hematol Oncol; 2010 Mar; 28(1):3-12. PubMed ID: 19645073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New agents for the treatment of acute myeloid leukemia.
    Tallman MS
    Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can FLT3 inhibitors overcome resistance in AML?
    Tam WF; Gary Gilliland D
    Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting epigenetic changes in acute myeloid leukemia.
    Blum W; Marcucci G
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):855-65, 882. PubMed ID: 16491631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia: a classification and treatment update.
    Iovino CS; Camacho LH
    Clin J Oncol Nurs; 2003; 7(5):535-40. PubMed ID: 14603550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment for acute myelogenous leukemia.
    DiNardo CD; Cortes JE
    Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies for relapsed and refractory acute myeloid leukemia.
    Mato AR; Morgans A; Luger SM
    Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
    Kuendgen A; Germing U
    Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group.
    Büchner T; Berdel WE; Haferlach C; Haferlach T; Schnittger S; Müller-Tidow C; Braess J; Spiekermann K; Kienast J; Staib P; Grüneisen A; Kern W; Reichle A; Maschmeyer G; Aul C; Lengfelder E; Sauerland MC; Heinecke A; Wörmann B; Hiddemann W
    J Clin Oncol; 2009 Jan; 27(1):61-9. PubMed ID: 19047294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
    Dombret H; Preudhomme C; Boissel N
    Curr Opin Hematol; 2009 Mar; 16(2):92-7. PubMed ID: 19468270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular targeting therapy by anti-VLA-4 monoclonal antibodies for AML].
    Niitsu Y; Matsunaga T
    Rinsho Ketsueki; 2005 Mar; 46(3):198-201. PubMed ID: 16447714
    [No Abstract]   [Full Text] [Related]  

  • 13. Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia.
    Amadori S; Stasi R
    Curr Opin Hematol; 2008 Mar; 15(2):95-100. PubMed ID: 18300754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy.
    Lübbert M; Müller-Tidow C; Hofmann WK; Koeffler HP
    J Cell Biochem; 2008 Aug; 104(6):2059-70. PubMed ID: 18613031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents in acute myeloid leukemia.
    Aribi A; Ravandi F; Giles F
    Cancer J; 2006; 12(2):77-91. PubMed ID: 16630396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.
    Roboz GJ
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S22-4. PubMed ID: 18760707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
    Tsukimoto I; Tawa A; Horibe K; Tabuchi K; Kigasawa H; Tsuchida M; Yabe H; Nakayama H; Kudo K; Kobayashi R; Hamamoto K; Imaizumi M; Morimoto A; Tsuchiya S; Hanada R
    J Clin Oncol; 2009 Aug; 27(24):4007-13. PubMed ID: 19620491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
    Braun T; Fenaux P
    Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute myeloid leukemia in the elderly.
    Dombret H; Raffoux E; Gardin C
    Semin Oncol; 2008 Aug; 35(4):430-8. PubMed ID: 18692693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric acute myeloid leukemia: towards high-quality cure of all patients.
    Kaspers GJ; Zwaan CM
    Haematologica; 2007 Nov; 92(11):1519-32. PubMed ID: 18024401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.